Triple Negative Breast Cancer (TNBC), until recently, used to pose an especially challenging diagnosis due to its aggressive nature. Responsible for around 10–15% of all cases of breast cancer, TNBC used to be seen as the most aggressive form of breast cancer. What makes this type of cancer different from other forms of breast cancer is the absence of the three receptors necessary for treatment – estrogen, progesterone, and HER2 protein receptors. Therefore, traditional hormone treatments and HER2-targeting drugs cannot be used. For a long time, chemotherapy was the main approach. Nevertheless, recent scientific discoveries have revolutionized the therapy. There have been significant scientific advancements resulting in FDA approvals that have changed the book on treatment, making TNBC a disease that can be managed by precise therapies. You should visit the best breast cancer doctor in Ahmedabad.
New Definitions for an Old Enemy: The Problem with the “Triple Negative” Label
TNBC is no longer considered a homogenous condition in the field of oncology. Advanced genomics show how much molecular diversity there is in triple negative tumors. Now, by using the knowledge of specific molecular pathways and markers in each patient’s individual tumor, doctors can move away from chemotherapy to a customized plan.Increasingly important markers for modern therapies include:PD-L1 Protein: High concentrations mean that the body’s immune system cannot recognize this cancer, making this an ideal case for immune therapy.BRCA1 & BRCA2 Mutations: These DNA repair defects create vulnerabilities for therapeutic enzyme inhibitors.Trop-2 Protein: An external protein located on the surface of TNBC cells and serving as a homing signal for drugs.
The Rise of Antibody-Drug Conjugates (ADCs): “Smart Bombs” in Action
But by far the most significant advance made in oncology is the adoption of Antibody-Drug Conjugates (ADCs) in first-line treatment. Frequently referred to as “smart bombs” in cellular biology, ADCs comprise an antibody modified to target certain tumor proteins, which are in turn associated with a potent chemotherapy drug. In this way, the drug is able to be delivered safely through the blood stream and attach to the cancer cells, where it then releases its highly toxic load inside. Patients seeking specialized care can consult a breast cancer doctor in Ahmedabad.
- Sacituzumab Govitecan (Trodelvy): Though used for a long time in advanced and pre-treated conditions, the FDA extended its use for first-line treatment of metastatic TNBC. It was seen that using this ADC targeting Trop-2 from the beginning of advanced conditions can reduce the chances of developing diseases or dying by 38%.
- Datopotamab Deruxtecan (Datroway): FDA approved this new ADC for patients suffering from unresectable or metastatic TNBC and who cannot be treated with immunotherapy. This therapy helps control cancer growth for almost double the duration than conventional chemotherapy.
Immunotherapy: Making the Cancer Cells Visible
Since TNBC is highly immunogenic, it usually uses a set of proteins to “escape” detection by the patient’s immune system. The mechanism of immunotherapy lies in preventing this process from happening, allowing T-cells to recognize the presence of cancer and destroy it.The current approach to treating early-stage and high-risk TNBC is the administration of Pembrolizumab (Keytruda) along with chemotherapy prior to surgery (neoadjuvant treatment). It greatly increases the pathological complete response (pCR) absence of any cancer cells when the surgery takes place which leads to increased chances of survival.In the case of metastatic tumors, the combination of Trodelvy and Keytruda is considered extremely efficient as a first-line treatment option for PD-L1 positive cancers.
PARP Inhibition as a Treatment Modality for Exploiting Flaws in DNA
For those who have BRCA1 or BRCA2 mutations as inherited genetic mutations, there is yet another special group of medications known as PARP inhibitors (for instance, Olaparib).Cells that are defective because of BRCA gene mutations find it difficult to repair the damaged DNA on their own. The PARP inhibitors prevent the second back-up enzyme in the cell from repairing DNA. Thus, the lack of options forces the cells to die.
Where to Go from Here: The Future of TNBC Treatment
The pace of TNBC research remains rapid and does not seem to be slowing. Clinical trials that test bispecific antibodies (that can target two molecules at once) and novel combinations of drugs that reduce the risk of developing resistance to treatment from the outset are currently being conducted. Oncowell Cancer Hospital provides patients with access to specialized cancer care and guidance throughout their treatment journey. There is nothing to take for granted when faced with a diagnosis of triple negative breast cancer. Yet, there is little room left to depend solely on non-targeted chemotherapy. Thanks to the advent of smart-bomb ADCs, precision immunotherapy, and individualized gene therapy, TNBC could soon become a curable disease. You just need to visit the best breast cancer doctor in Ahmedabad.